JP2022524077A5 - - Google Patents
Info
- Publication number
- JP2022524077A5 JP2022524077A5 JP2021552999A JP2021552999A JP2022524077A5 JP 2022524077 A5 JP2022524077 A5 JP 2022524077A5 JP 2021552999 A JP2021552999 A JP 2021552999A JP 2021552999 A JP2021552999 A JP 2021552999A JP 2022524077 A5 JP2022524077 A5 JP 2022524077A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- optionally substituted
- alkyl
- pharmaceutically acceptable
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962815553P | 2019-03-08 | 2019-03-08 | |
| US62/815,553 | 2019-03-08 | ||
| PCT/US2020/021479 WO2020185593A1 (en) | 2019-03-08 | 2020-03-06 | Azetidinyl 0-glyc0pr0tein-2-acetamid0-2-deoxy-3-d-gluc0pyran0sidase inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022524077A JP2022524077A (ja) | 2022-04-27 |
| JP2022524077A5 true JP2022524077A5 (enExample) | 2023-03-14 |
| JP7663503B2 JP7663503B2 (ja) | 2025-04-16 |
Family
ID=69960768
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021552999A Active JP7663503B2 (ja) | 2019-03-08 | 2020-03-06 | アゼチジニルｏ－糖タンパク質－２－アセトアミド－２－デオキシ－３－ｄ－グルコピラノシダーゼ阻害剤 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US12421224B2 (enExample) |
| EP (1) | EP3935055A1 (enExample) |
| JP (1) | JP7663503B2 (enExample) |
| MA (1) | MA55203A (enExample) |
| WO (1) | WO2020185593A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026021588A1 (zh) * | 2024-07-26 | 2026-01-29 | 浙江同源康医药股份有限公司 | Oga抑制剂及其应用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| EP2780014A4 (en) | 2011-11-18 | 2015-07-01 | Constellation Pharmaceuticals Inc | MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF |
| US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013078320A1 (en) | 2011-11-21 | 2013-05-30 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| JP5989805B2 (ja) | 2012-02-10 | 2016-09-07 | コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． | メチル基変更酵素の調節物質、組成物及びその使用 |
| MA38341B1 (fr) | 2013-02-11 | 2018-11-30 | Constellation Pharmaceuticals Inc | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
| PT2970272T (pt) * | 2013-03-14 | 2019-06-05 | Merck Patent Gmbh | Inibidores de glicosidase |
| US9745305B2 (en) | 2013-03-15 | 2017-08-29 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
| US9969716B2 (en) | 2013-08-15 | 2018-05-15 | Constellation Pharmaceuticals, Inc. | Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof |
| EP3555087A1 (en) | 2016-12-16 | 2019-10-23 | Janssen Pharmaceutica NV | Monocyclic oga inhibitor compounds |
| WO2018154133A1 (en) | 2017-02-27 | 2018-08-30 | Janssen Pharmaceutica Nv | [1,2,4]-triazolo [1,5-a]-pyrimidinyl derivatives substituted with piperidine, morpholine or piperazine as oga inhibitors |
-
2020
- 2020-03-06 JP JP2021552999A patent/JP7663503B2/ja active Active
- 2020-03-06 MA MA055203A patent/MA55203A/fr unknown
- 2020-03-06 WO PCT/US2020/021479 patent/WO2020185593A1/en not_active Ceased
- 2020-03-06 EP EP20714094.8A patent/EP3935055A1/en active Pending
- 2020-03-06 US US17/435,125 patent/US12421224B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021518340A5 (enExample) | ||
| JP2022500472A5 (enExample) | ||
| Asahina et al. | Synthesis and antibacterial activity of 1-(2-fluorovinyl)-7-substituted-4-quinolone-3-carboxylic acid derivatives, conformationally restricted analogues of fleroxacin | |
| Fang et al. | Synthesis, antibacterial, and cytotoxic evaluation of certain 7-substituted norfloxacin derivatives | |
| JP2019506430A5 (enExample) | ||
| JP2019510006A5 (enExample) | ||
| JP2014524911A5 (enExample) | ||
| HRP20211272T1 (hr) | 24-hidroksisteroli supstituirani na poziciji 11 za uporabu u liječenju stanja povezanih sa nmda | |
| JP2020535165A5 (enExample) | ||
| JP2022519639A5 (enExample) | ||
| JP2022510430A5 (enExample) | ||
| AU2016346207B2 (en) | Intermediates to prepare pyridazinone herbicides, and a process to prepare them | |
| CA2556653A1 (en) | Tetrahydroquinolinones and their use as antagonists of metabotropic glutamate receptors | |
| JP2012502884A5 (enExample) | ||
| JP2013542267A5 (enExample) | ||
| JP2022524077A5 (enExample) | ||
| JP2015516429A5 (enExample) | ||
| JP2018521034A5 (enExample) | ||
| JP2023501949A5 (enExample) | ||
| Jameson et al. | Application of crystallization-induced asymmetric transformation to a general, scalable method for the resolution of 2, 8-disubstituted Tröger’s base derivatives | |
| HRP20240557T1 (hr) | Inhibitori kalikreina ljudske plazme | |
| Tarui et al. | Enantioselective synthesis of α, α-difluoro-β-lactams using amino alcohol ligands | |
| JP2006504690A5 (enExample) | ||
| Weng et al. | Synthesis of 2-aminopyridines via a base-promoted cascade reaction of N-propargylic β-enaminones with formamides | |
| JP2012532125A5 (enExample) |